Donanemab：澳大利亚阿尔茨海默病改善治疗的曙光。

IF 1.2 4区医学 Q4 PSYCHIATRY

Australasian Psychiatry Pub Date : 2025-06-23 DOI:10.1177/10398562251355157

Samantha M Loi, Matthew Jy Kang

{"title":"Donanemab：澳大利亚阿尔茨海默病改善治疗的曙光。","authors":"Samantha M Loi, Matthew Jy Kang","doi":"10.1177/10398562251355157","DOIUrl":null,"url":null,"abstract":"On 22 May 2025, the Therapeutic Goods Administration (TGA) announced that the anti-amyloid monoclonal antibody donanemab (Eli Lilly, Kisunla) was approved in Australia for the treatment of Alzheimer's disease (AD). This has been heralded by some as a breakthrough for the treatment of AD, reflecting a turning point from symptomatic treatments to disease-modifying therapies. Psychiatrists should understand this scientific context, as it underpins both the hope and the limits of what donanemab can achieve. The roll-out of disease-modifying treatment comes with significant challenges but also provides a unique opportunity to improve care for people with AD and other dementias.","PeriodicalId":8630,"journal":{"name":"Australasian Psychiatry","volume":" ","pages":"10398562251355157"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia.\",\"authors\":\"Samantha M Loi, Matthew Jy Kang\",\"doi\":\"10.1177/10398562251355157\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"On 22 May 2025, the Therapeutic Goods Administration (TGA) announced that the anti-amyloid monoclonal antibody donanemab (Eli Lilly, Kisunla) was approved in Australia for the treatment of Alzheimer's disease (AD). This has been heralded by some as a breakthrough for the treatment of AD, reflecting a turning point from symptomatic treatments to disease-modifying therapies. Psychiatrists should understand this scientific context, as it underpins both the hope and the limits of what donanemab can achieve. The roll-out of disease-modifying treatment comes with significant challenges but also provides a unique opportunity to improve care for people with AD and other dementias.\",\"PeriodicalId\":8630,\"journal\":{\"name\":\"Australasian Psychiatry\",\"volume\":\" \",\"pages\":\"10398562251355157\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-06-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10398562251355157\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10398562251355157","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

摘要

2025年5月22日，美国药品管理局（TGA）宣布，抗淀粉样蛋白单克隆抗体donanemab（礼来公司Kisunla）在澳大利亚被批准用于治疗阿尔茨海默病（AD）。这被一些人视为阿尔茨海默病治疗的突破，反映了从对症治疗到改善疾病治疗的转折点。精神科医生应该理解这一科学背景，因为它既支撑着donanemab所能达到的希望，也支撑着它的局限性。改善疾病的治疗方法的推出带来了重大挑战，但也为改善阿尔茨海默病和其他痴呆症患者的护理提供了一个独特的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia.

On 22 May 2025, the Therapeutic Goods Administration (TGA) announced that the anti-amyloid monoclonal antibody donanemab (Eli Lilly, Kisunla) was approved in Australia for the treatment of Alzheimer's disease (AD). This has been heralded by some as a breakthrough for the treatment of AD, reflecting a turning point from symptomatic treatments to disease-modifying therapies. Psychiatrists should understand this scientific context, as it underpins both the hope and the limits of what donanemab can achieve. The roll-out of disease-modifying treatment comes with significant challenges but also provides a unique opportunity to improve care for people with AD and other dementias.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Australasian Psychiatry 医学-精神病学

CiteScore

2.80

自引率

5.60%

发文量

159

审稿时长

6-12 weeks

期刊介绍： Australasian Psychiatry is the bi-monthly journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP) that aims to promote the art of psychiatry and its maintenance of excellence in practice. The journal is peer-reviewed and accepts submissions, presented as original research; reviews; descriptions of innovative services; comments on policy, history, politics, economics, training, ethics and the Arts as they relate to mental health and mental health services; statements of opinion and letters. Book reviews are commissioned by the editor. A section of the journal provides information on RANZCP business and related matters.